Do analysts recommend APT or CODX?

Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 2,113.11%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Co-Diagnostics is more favorable than Alpha Pro Tech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alpha Pro Tech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Co-Diagnostics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is APT or CODX more profitable?

Alpha Pro Tech has a net margin of 6.99% compared to Co-Diagnostics' net margin of -6,760.63%. Alpha Pro Tech's return on equity of 6.70% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Alpha Pro Tech 6.99% 6.70% 5.76% Co-Diagnostics -6,760.63% -164.92% -141.15%

Do analysts prefer CODX or SKYA?

Co-Diagnostics currently has a consensus price target of $67.50, suggesting a potential upside of 2,113.11%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, equities analysts clearly believe Co-Diagnostics is more favorable than SkyAI, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Co-Diagnostics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SkyAI, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LUNG or CODX more profitable?

Pulmonx has a net margin of -60.09% compared to Co-Diagnostics' net margin of -6,760.63%. Pulmonx's return on equity of -92.94% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -60.09% -92.94% -39.80% Co-Diagnostics -6,760.63% -164.92% -141.15%

Does the media prefer LUNG or CODX?

In the previous week, Co-Diagnostics had 1 more articles in the media than Pulmonx. MarketBeat recorded 4 mentions for Co-Diagnostics and 3 mentions for Pulmonx. Co-Diagnostics' average media sentiment score of 0.72 beat Pulmonx's score of 0.62 indicating that Co-Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulmonx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is COCH or CODX more profitable?

Co-Diagnostics has a net margin of -6,760.63% compared to Envoy Medical's net margin of -9,875.64%. Envoy Medical's return on equity of 0.00% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Envoy Medical -9,875.64% N/A -177.92% Co-Diagnostics -6,760.63% -164.92% -141.15%

Does the media prefer COCH or CODX?

In the previous week, Co-Diagnostics had 2 more articles in the media than Envoy Medical. MarketBeat recorded 4 mentions for Co-Diagnostics and 2 mentions for Envoy Medical. Co-Diagnostics' average media sentiment score of 0.72 beat Envoy Medical's score of 0.63 indicating that Co-Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Envoy Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Co-Diagnostics (CODX) Competitors

$3.05 -0.52 (-14.57%)

Closing price 06/25/2026 04:00 PM Eastern

Extended Trading

$3.22 +0.17 (+5.41%)

As of 05:08 AM Eastern

Compare

CODX vs. APT, SKYA, DRIO, LUNG, and COCH

Should you buy Co-Diagnostics stock or one of its competitors? MarketBeat compares Co-Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Co-Diagnostics include Alpha Pro Tech (APT), SkyAI, Inc. Common Stock (SKYA), DarioHealth (DRIO), Pulmonx (LUNG), and Envoy Medical (COCH). These companies are all part of the "medical equipment" industry.

How does Co-Diagnostics compare to Alpha Pro Tech?

Alpha Pro Tech (NYSE:APT) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

In the previous week, Co-Diagnostics had 4 more articles in the media than Alpha Pro Tech. MarketBeat recorded 4 mentions for Co-Diagnostics and 0 mentions for Alpha Pro Tech. Co-Diagnostics' average media sentiment score of 0.72 beat Alpha Pro Tech's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alpha Pro Tech	Neutral
Co-Diagnostics	Positive

22.7% of Alpha Pro Tech shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 16.2% of Alpha Pro Tech shares are held by company insiders. Comparatively, 5.4% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Alpha Pro Tech has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Pro Tech	$59.91M	0.88	$4.19M	$0.35	14.71
Co-Diagnostics	$620K	18.15	-$46.90M	-$15.77	N/A

Alpha Pro Tech has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.74, suggesting that its stock price is 174% more volatile than the broader market.

Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 2,113.11%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Co-Diagnostics is more favorable than Alpha Pro Tech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Pro Tech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alpha Pro Tech has a net margin of 6.99% compared to Co-Diagnostics' net margin of -6,760.63%. Alpha Pro Tech's return on equity of 6.70% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Pro Tech	6.99%	6.70%	5.76%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

Summary

Alpha Pro Tech beats Co-Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Co-Diagnostics compare to SkyAI, Inc. Common Stock?

Co-Diagnostics (NASDAQ:CODX) and SkyAI, Inc. Common Stock (NASDAQ:SKYA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Co-Diagnostics has a beta of 2.74, indicating that its share price is 174% more volatile than the broader market. Comparatively, SkyAI, Inc. Common Stock has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

SkyAI, Inc. Common Stock has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,760.63%. SkyAI, Inc. Common Stock's return on equity of -157.91% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%
SkyAI, Inc. Common Stock	N/A	-157.91%	-154.40%

Co-Diagnostics currently has a consensus price target of $67.50, suggesting a potential upside of 2,113.11%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, equities analysts clearly believe Co-Diagnostics is more favorable than SkyAI, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SkyAI, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Co-Diagnostics had 3 more articles in the media than SkyAI, Inc. Common Stock. MarketBeat recorded 4 mentions for Co-Diagnostics and 1 mentions for SkyAI, Inc. Common Stock. SkyAI, Inc. Common Stock's average media sentiment score of 1.89 beat Co-Diagnostics' score of 0.72 indicating that SkyAI, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Co-Diagnostics	Positive
SkyAI, Inc. Common Stock	Very Positive

Co-Diagnostics has higher revenue and earnings than SkyAI, Inc. Common Stock. SkyAI, Inc. Common Stock is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	18.15	-$46.90M	-$15.77	N/A
SkyAI, Inc. Common Stock	$200K	201.02	-$282.50M	-$1.63	N/A

15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 17.2% of SkyAI, Inc. Common Stock shares are held by institutional investors. 5.4% of Co-Diagnostics shares are held by company insiders. Comparatively, 20.0% of SkyAI, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Co-Diagnostics beats SkyAI, Inc. Common Stock on 9 of the 16 factors compared between the two stocks.

How does Co-Diagnostics compare to DarioHealth?

Co-Diagnostics (NASDAQ:CODX) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 33.4% of DarioHealth shares are held by institutional investors. 5.4% of Co-Diagnostics shares are held by insiders. Comparatively, 3.5% of DarioHealth shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

DarioHealth has higher revenue and earnings than Co-Diagnostics. DarioHealth is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	18.15	-$46.90M	-$15.77	N/A
DarioHealth	$22.36M	2.01	-$41.71M	-$8.88	N/A

Co-Diagnostics currently has a consensus target price of $67.50, indicating a potential upside of 2,113.11%. DarioHealth has a consensus target price of $10.50, indicating a potential upside of 70.73%. Given Co-Diagnostics' higher possible upside, research analysts plainly believe Co-Diagnostics is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

DarioHealth has a net margin of -192.23% compared to Co-Diagnostics' net margin of -6,760.63%. DarioHealth's return on equity of -60.52% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%
DarioHealth	-192.23%	-60.52%	-37.08%

Co-Diagnostics has a beta of 2.74, meaning that its stock price is 174% more volatile than the broader market. Comparatively, DarioHealth has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

In the previous week, Co-Diagnostics had 3 more articles in the media than DarioHealth. MarketBeat recorded 4 mentions for Co-Diagnostics and 1 mentions for DarioHealth. DarioHealth's average media sentiment score of 1.87 beat Co-Diagnostics' score of 0.72 indicating that DarioHealth is being referred to more favorably in the news media.

Company	Overall Sentiment
Co-Diagnostics	Positive
DarioHealth	Very Positive

Summary

DarioHealth beats Co-Diagnostics on 8 of the 14 factors compared between the two stocks.

How does Co-Diagnostics compare to Pulmonx?

Pulmonx (NASDAQ:LUNG) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Pulmonx currently has a consensus price target of $5.58, indicating a potential upside of 346.67%. Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 2,113.11%. Given Co-Diagnostics' higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pulmonx has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.74, meaning that its stock price is 174% more volatile than the broader market.

Co-Diagnostics has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.58	-$54M	-$1.30	N/A
Co-Diagnostics	$620K	18.15	-$46.90M	-$15.77	N/A

Pulmonx has a net margin of -60.09% compared to Co-Diagnostics' net margin of -6,760.63%. Pulmonx's return on equity of -92.94% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

In the previous week, Co-Diagnostics had 1 more articles in the media than Pulmonx. MarketBeat recorded 4 mentions for Co-Diagnostics and 3 mentions for Pulmonx. Co-Diagnostics' average media sentiment score of 0.72 beat Pulmonx's score of 0.62 indicating that Co-Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 6.8% of Pulmonx shares are owned by company insiders. Comparatively, 5.4% of Co-Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Pulmonx beats Co-Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Co-Diagnostics compare to Envoy Medical?

Envoy Medical (NASDAQ:COCH) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Envoy Medical has higher earnings, but lower revenue than Co-Diagnostics. Envoy Medical is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envoy Medical	$240K	215.55	-$23.76M	-$1.01	N/A
Co-Diagnostics	$620K	18.15	-$46.90M	-$15.77	N/A

Co-Diagnostics has a net margin of -6,760.63% compared to Envoy Medical's net margin of -9,875.64%. Envoy Medical's return on equity of 0.00% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envoy Medical	-9,875.64%	N/A	-177.92%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

In the previous week, Co-Diagnostics had 2 more articles in the media than Envoy Medical. MarketBeat recorded 4 mentions for Co-Diagnostics and 2 mentions for Envoy Medical. Co-Diagnostics' average media sentiment score of 0.72 beat Envoy Medical's score of 0.63 indicating that Co-Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envoy Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Envoy Medical presently has a consensus target price of $2.50, suggesting a potential upside of 271.53%. Co-Diagnostics has a consensus target price of $67.50, suggesting a potential upside of 2,113.11%. Given Co-Diagnostics' higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than Envoy Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Envoy Medical has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.74, meaning that its share price is 174% more volatile than the broader market.

8.6% of Envoy Medical shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 7.1% of Envoy Medical shares are held by company insiders. Comparatively, 5.4% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Co-Diagnostics beats Envoy Medical on 9 of the 14 factors compared between the two stocks.

Get Co-Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CODX vs. The Competition

Export

Metric	Co-Diagnostics	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.16M	$9.11B	$6.61B	$12.27B
Dividend Yield	N/A	1.71%	2.67%	5.88%
P/E Ratio	-0.19	25.50	26.01	23.97
Price / Sales	18.15	16.84	538.25	99.72
Price / Cash	N/A	106.49	46.33	53.91
Price / Book	0.33	5.92	10.68	6.32
Net Income	-$46.90M	$177.22M	$3.57B	$337.22M
7 Day Performance	-9.50%	2.32%	0.80%	-1.23%
1 Month Performance	-66.52%	4.70%	0.23%	-0.63%
1 Year Performance	-61.91%	11.85%	30.84%	27.95%

Co-Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CODX Co-Diagnostics	3.391 of 5 stars	$3.05 -14.6%	$67.50 +2,113.1%	-63.2%	$13.16M	$620K	N/A	100	News Coverage Short Interest Decrease
APT Alpha Pro Tech	N/A	$5.26 -1.1%	N/A	+8.4%	$53.74M	$59.91M	14.22	120	Gap Down
SKYA SkyAI, Inc. Common Stock	1.2541 of 5 stars	$1.27 +1.2%	N/A	-82.4%	$53.54M	$200K	N/A	55	Positive News High Trading Volume
DRIO DarioHealth	2.575 of 5 stars	$7.22 +1.0%	$10.50 +45.4%	-55.8%	$52.78M	$22.36M	N/A	200	Positive News
LUNG Pulmonx	3.1215 of 5 stars	$1.24 -3.1%	$5.58 +350.3%	-52.5%	$52.38M	$90.50M	N/A	250	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CODX) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Co-Diagnostics (CODX) Competitors

CODX vs. APT, SKYA, DRIO, LUNG, and COCH

How does Co-Diagnostics compare to Alpha Pro Tech?

Summary

How does Co-Diagnostics compare to SkyAI, Inc. Common Stock?

Summary

How does Co-Diagnostics compare to DarioHealth?

Summary

How does Co-Diagnostics compare to Pulmonx?

Summary

How does Co-Diagnostics compare to Envoy Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Co-Diagnostics (CODX) Competitors

CODX vs. APT, SKYA, DRIO, LUNG, and COCH

How does Co-Diagnostics compare to Alpha Pro Tech?

Does the media favor APT or CODX?

Do institutionals & insiders believe in APT or CODX?

Which has better valuation & earnings, APT or CODX?

Which has more risk & volatility, APT or CODX?

Do analysts recommend APT or CODX?

Is APT or CODX more profitable?

Summary

How does Co-Diagnostics compare to SkyAI, Inc. Common Stock?

Which has more volatility and risk, CODX or SKYA?

Is CODX or SKYA more profitable?

Do analysts prefer CODX or SKYA?

Does the media refer more to CODX or SKYA?

Which has preferable valuation and earnings, CODX or SKYA?

Do insiders and institutionals hold more shares of CODX or SKYA?

Summary

How does Co-Diagnostics compare to DarioHealth?

Do institutionals and insiders believe in CODX or DRIO?

Which has higher valuation & earnings, CODX or DRIO?

Do analysts rate CODX or DRIO?

Is CODX or DRIO more profitable?

Which has more risk and volatility, CODX or DRIO?

Does the media refer more to CODX or DRIO?

Summary

How does Co-Diagnostics compare to Pulmonx?

Do analysts prefer LUNG or CODX?

Which has more volatility & risk, LUNG or CODX?

Which has stronger valuation & earnings, LUNG or CODX?

Is LUNG or CODX more profitable?

Does the media prefer LUNG or CODX?

Do insiders and institutionals have more ownership in LUNG or CODX?

Summary

How does Co-Diagnostics compare to Envoy Medical?

Which has higher earnings & valuation, COCH or CODX?

Is COCH or CODX more profitable?

Does the media prefer COCH or CODX?

Do analysts prefer COCH or CODX?

Which has more volatility and risk, COCH or CODX?

Do institutionals and insiders hold more shares of COCH or CODX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools